Hiroyoshi Doihara
   Department   Kawasaki Medical School  Kawasaki Medical School, Department of General Surgery,
   Position   Professor with Special Assignment
Article types 原著
Language English
Peer review Peer reviewed
Title Effect of local surgery on outcomes of stage IV breast cancer.
Journal Formal name：Translational cancer research
Abbreviation：Transl Cancer Res
ISSN code：22196803/2218676X
Domestic / ForeginForegin
Volume, Issue, Page 9(8),pp.5102-5107
Author and coauthor Tsukioki Takahiro, Shien Tadahiko, Doihara Hiroyoshi
Publication date 2020/08
Summary Metastatic breast cancer (MBC), including de novo stage IV, is regarded as being incurable and the mainstay of clinical management is systemic therapy. Traditionally, locoregional surgery is performed only for local control, such as to prevent ulceration and bleeding. In recent years, however, both retrospective and prospective studies have demonstrated the prognostic efficacy of primary surgery for de novo stage IV patients. Therefore, we conducted a meta-analysis to evaluate whether surgical therapy contributes to overall survival (OS) extension. We searched for clinical trials published in electronic databases (PubMed, Embase, and the Cochrane databases) and performed a meta-analysis of the data collected. There were five prospective randomized controlled phase III trials (RCTs). The results of three have been reported. According to our meta-analysis of these RCTs, primary surgery for de novo stage IV breast cancer patients significantly improves OS. However, the Tata trial showed that systemic therapy does not achieve a sufficient effect. Another trial, conducted in Turkey, had statistical shortcomings and patient randomization was not adequately performed The ABCSG (Austrian Breast and Colorectal Cancer Study Group) trial had too few subjects. Meta-analysis of 12 retrospective studies showed that patients with stage IV breast cancer receiving surgery as the initial treatment experienced longer OS (HR: 0.65, P<0.00001). Based on our meta-analysis of three reported RCTs, surgery as the primary treatment does not significantly impact the outcomes of de novo stage IV breast cancer patients. However, these trials had limitations. We await the results of the remaining two ongoing RCTs (ECOG 2108 and JCOG 1017). These trials are anticipated to resolve current controversies and provide many eagerly awaited answers.
DOI 10.21037/tcr.2020.01.60
PMID 35117876